Hubro Therapeutics is a company that develops proprietary neo-peptide technology platforms and immunotherapies for treating cancer. It develops target mutations, lead candidates, and neoantigen cancer vaccines for the activation of anti-cancer specific T cell immune responses, Framutide, a peptide vaccine corresponding to a fragment of the neo-antigen expressed by cancer cells having a frameshift mutation in the transforming growth factor b receptor 2 (TGFbR2) gene.